Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : CLN-081
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Cullinan Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Taiho, Cullinan’s Zipalertinib Meets Phase 2b NSCLC Trial Endpoint
Details : CLN-081 (zipalertinib) is an orally available small molecule designed to target activating mutations in EGFR. It is being evaluated for the treatment of EGFR non-small cell lung cancer.
Product Name : CLN-081
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 28, 2025
Lead Product(s) : CLN-081
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Cullinan Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cedazuridine,Decitabine
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : National Cancer Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Taiho Oncology Announces Decitabine and Cedazuridine in NIH Trials
Details : Inqovi is a combination of decitabine, a nucleoside metabolic inhibitor and cedazuridine, a cytidine deaminase inhibitor. It is being evaluated for IDH2-Mutated Myelodysplastic Syndrome.
Product Name : Inqovi
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
January 14, 2025
Lead Product(s) : Cedazuridine,Decitabine
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : National Cancer Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Futibatinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CHMP Issues Positive Opinion for Futibatinib for The Treatment of Adults with Cholangiocarcinoma
Details : TAS-120 (futibatinib) is an oral, potent, selective, and irreversible tyrosine kinase inhibitor of FGFR1, 2, 3 and 4 being studied as a potential treatment for patients with advanced solid tumors with FGFR1-4 genetic aberrations, including cholangiocarci...
Product Name : Lytgobi
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 27, 2023
Lead Product(s) : Futibatinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Trifluridine,Bevacizumab,Tipiracil HCl
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lonsurf consists of a thymidine-based nucleoside analog, trifluridine, and the thymidine phosphorylase inhibitor, tipiracil, it has demonstrated anti-tumor activity against refractory colorectal cancer, in combination with bevacizumab.
Product Name : Lonsurf
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
April 18, 2023
Lead Product(s) : Trifluridine,Bevacizumab,Tipiracil HCl
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Futibatinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lytgobi (futibatinib) is a small molecule kinase inhibitor of FGFR 1, 2, 3, and 4. It has demostrated anti-tumour activity by inhibiting FGFR phosphorylation and downstream signaling and decreased cell viability in cancer cell lines with FGFR alterations...
Product Name : Lytgobi
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 07, 2023
Lead Product(s) : Futibatinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CLN-081,Cisplatin,Pemetrexed
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TAS6417 (zipalertinib) is an orally available small molecule designed to target activating mutations in EGFR. The molecule was engineered to inhibit EGFR variants with exon 20 insertion mutations, while sparing wild-type EGFR.
Product Name : TAS6417
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 08, 2023
Lead Product(s) : CLN-081,Cisplatin,Pemetrexed
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Trifluridine,Bevacizumab,Tipiracil HCl
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lonsurf (trifluridine/tipiracil), an oral nucleoside antitumor agent, got approved as a single agent or in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (mCRC).
Product Name : Lonsurf
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
February 08, 2023
Lead Product(s) : Trifluridine,Bevacizumab,Tipiracil HCl
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Futibatinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lytgobi (futibatinib) is a small molecule kinase inhibitor of FGFR 1, 2, 3, and 4. It has demostrated anti-tumour activity by inhibiting FGFR phosphorylation and downstream signaling and decreased cell viability in cancer cell lines with FGFR alterations...
Product Name : Lytgobi
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 18, 2023
Lead Product(s) : Futibatinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Trifluridine,Tipiracil HCl
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Servier
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Data for LONSURF® (trifluridine and tipiracil) in previously treated patients with metastatic gastric cancer and metastatic gastroesophageal junction adenocarcinoma will be presented during the 2021 American Society of Clinical Oncology Gastrointestinal...
Product Name : Lonsurf
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
December 01, 2021
Lead Product(s) : Trifluridine,Tipiracil HCl
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Servier
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Futibatinib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Key presentations include: Primary results of phase 2 FOENIX-CCA2: the irreversible FGFR1-4 inhibitor futibatinib in intrahepatic cholangiocarcinoma with FGFR2 fusions/rearrangements: Acquired resistance to ATP-competitive and irreversible FGFR inhibitor...
Product Name : Lytgobi
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 04, 2021
Lead Product(s) : Futibatinib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable